Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA -mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP) Meeting Abstract

  

Authors:	Gallagher, E. J.; Moore, H.; Lacouture, M. E.; Dent, S. F.; Farooki, A.; Goncalves, M. D.; Isaacs, C.; Johnston, A.; Juric, D.; Quandt, Z.; Spring, L.; Berman, B.; Decker, M.; Hortobagyi, G. N.; Kaffenberger, B.; Kwong, B. Y.; Pluard, T. J.; Rao, R. D.; Schwartzberg, L. S.; Broder, M. S.
Abstract Title:	Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA -mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP)
Meeting Title:	2022 ASCO Quality Care Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	28 Suppl.
Meeting Dates:	2022 Sep 30-Oct 1
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-10-01
Language:	English
DOI:	10.1200/JCO.2022.40.28_suppl.422
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=159446424&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting Abstract: 422 -- Meeting was conducted online as well as in person -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/199568